Autoimmune diseases represent a significant medical challenge where the body's immune system mistakenly attacks its own tissues, leading to chronic inflammation and serious health ramifications. The traditional treatment regime generally suppresses the immune system broadly, offering only symptomatic relief and increasing susceptibility to infections. However, recent strides in understanding the immune system coupled with breakthroughs in technology have sparked a new wave of treatments aimed at specific pathogenic pathways to restore balance and potentially offer a lasting cure without compromising overall immune function.
This research topic aims to explore the spectrum of innovative therapies that specifically target critical components driving disease progression in autoimmune conditions. We aim to highlight recent advancements in technologies such as CAR T therapies, targeted protein degradation, and nucleotide-based therapies, which hold the promise of drug-free remission and potential cures by focusing precisely on pathogenic cells without overall immune suppression.
To gather further insights into these promising avenues, we welcome articles addressing, but not limited to, the following themes:
o Advances in Cell therapies:
o Cell depletion therapies (e.g., CAR-T cell therapy, CAR-NK cell therapy)
o Tolerance induction therapies (e.g., tolerogenic dendritic cells, engineered Tregs like TCR-Treg cells and CAR-Treg cells)
o Novel LNP-based mRNA therapies:
o In situ CAR T therapies
o In situ cell-reprogramming mRNA therapies
o Cutting-edge antibody-based therapies:
o Bispecific antibodies, proteasome-targeted nanobodies (e.g., LYTAC, AbTAC, AUTAC)
o Small-molecule engager-based therapies:
o PROTAC, molecule glue, etc.
o Forefront nucleic acid-based therapies:
o AAV, lentivirus, nanoparticles, mRNA, ASO, siRNA, plasmid, oligonucleotide
o Other pioneering curative treatments:
o Antigen-specific tolerance induction vaccines
Through this research topic, we aim to chart the current landscape and future directions in autoimmune disease therapeutics, fostering a deeper discourse around therapeutically curative options and their development.
Note that Ce Wang, Guobao Chen, Qi Wan and Feng Dong are AbbVie employees.
Autoimmune diseases represent a significant medical challenge where the body's immune system mistakenly attacks its own tissues, leading to chronic inflammation and serious health ramifications. The traditional treatment regime generally suppresses the immune system broadly, offering only symptomatic relief and increasing susceptibility to infections. However, recent strides in understanding the immune system coupled with breakthroughs in technology have sparked a new wave of treatments aimed at specific pathogenic pathways to restore balance and potentially offer a lasting cure without compromising overall immune function.
This research topic aims to explore the spectrum of innovative therapies that specifically target critical components driving disease progression in autoimmune conditions. We aim to highlight recent advancements in technologies such as CAR T therapies, targeted protein degradation, and nucleotide-based therapies, which hold the promise of drug-free remission and potential cures by focusing precisely on pathogenic cells without overall immune suppression.
To gather further insights into these promising avenues, we welcome articles addressing, but not limited to, the following themes:
o Advances in Cell therapies:
o Cell depletion therapies (e.g., CAR-T cell therapy, CAR-NK cell therapy)
o Tolerance induction therapies (e.g., tolerogenic dendritic cells, engineered Tregs like TCR-Treg cells and CAR-Treg cells)
o Novel LNP-based mRNA therapies:
o In situ CAR T therapies
o In situ cell-reprogramming mRNA therapies
o Cutting-edge antibody-based therapies:
o Bispecific antibodies, proteasome-targeted nanobodies (e.g., LYTAC, AbTAC, AUTAC)
o Small-molecule engager-based therapies:
o PROTAC, molecule glue, etc.
o Forefront nucleic acid-based therapies:
o AAV, lentivirus, nanoparticles, mRNA, ASO, siRNA, plasmid, oligonucleotide
o Other pioneering curative treatments:
o Antigen-specific tolerance induction vaccines
Through this research topic, we aim to chart the current landscape and future directions in autoimmune disease therapeutics, fostering a deeper discourse around therapeutically curative options and their development.
Note that Ce Wang, Guobao Chen, Qi Wan and Feng Dong are AbbVie employees.